Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05404763
Other study ID # 2020_56
Secondary ID 2021-A03205-36
Status Recruiting
Phase
First received
Last updated
Start date February 2, 2023
Est. completion date July 2, 2025

Study information

Verified date May 2024
Source University Hospital, Lille
Contact Cécile Chenivesse, MD,PhD
Phone 0320445962
Email cecile.chenivesse@chru-lille.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects. Exercise limitation due to exercise-induced bronchoconstriction, dynamic lung hyperinflation and comorbidity may be a strong determinant of the disease burden. Mepolizumab is a monoclonal anti-interleukin-5 (IL-5) antibody that reduces the rate of severe exacerbations, asthma symptoms and oral glucocorticoid requirement, and improves quality of life and work productivity in severe eosinophilic asthma. However, its impact on physical activity and exercise tolerance is unknown. We hypothesize that a 6-month treatment with mepolizumab is associated with an improvement in daily life physical activity and exercise tolerance in relation with enhanced ventilatory mechanics.


Recruitment information / eligibility

Status Recruiting
Enrollment 102
Est. completion date July 2, 2025
Est. primary completion date February 2, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age between 18 and 75 years at the time of inclusion - Asthma diagnosed for at least one year including a history of 1. FEV1 and/or FVC reversibility of more than 12% and than 200 ml documented in the patient's record 2. OR FEV1 variability of more than 20% between two visits 3. OR positive methacholine test - Severe uncontrolled asthma monitored for at least six months in the investigation center with at least two assessments: 1. high-dose of inhaled corticosteroids (ICS >1,000 µg/day of beclometasone equivalent) in combination with another controller at a stable dosage for at least three months 2. ACQ-5 score >1.5 and/or more than two severe exacerbations (i.e exacerbation requiring = 3 days of systemic corticosteroids, hospitalization or admission at the emergency department) in the past year 3. Blood eosinohils =300/mm3 within the 12 past months 4. Decision to introduce mepolizumab according to regulatory approval 5. Patient agreement to receive Mepolizumab - Body mass index (BMI) within the range [18.5 - 35] kg/m2. - Able to give signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol Exclusion Criteria: - Body Mass Index <18.5 or >35 kg/m2 - Active smoker or active smoking during the last 6 months or cumulative > 10 pack-years - All conditions responsible for physical disability (neurological, orthopedic, psychiatric, non-exhaustive list) or other condition limiting exercise in the investigator's opinion - Any chronic respiratory or cardiac pathology which may interfere with the assessment of asthma according to the investigator's opinion - Prior treatment with mepolizumab or benralizumab - Bronchial thermoplasty during the past 12 months - Contraindication to mepolizumab - Non-coverage by the social security insurance - Pregnant, breastfeeding, or lactating women - Patient unable to receive information - Refusal to sign the consent form - Unwillingness or inability to follow the study procedures, in the opinion of the investigator - Person deprived of the liberty Person benefiting from a system of legal protection (guardianship…)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Lille University Hospital Lille

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Lille GlaxoSmithKline

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of daily steps after 6 months of treatment with mepolizumab
Secondary Time with moderate physical activity (between 3 and 6 METs) and intense activity (>6 METs) Baseline, at 3 months and at 6 months
Secondary Percentage of time spent with moderate physical activity (between 3 and 6 METs) and intense activity (>6 METs) Baseline, at 3 months and at 6 months
Secondary Ricci and Gagnon questionnaire score • Ricci and Gagnon questionnaire is Score of physical activity , 9 items, total range score from 6 to 45, higher score indicating a higher level of physical activity Baseline, at 3 months and at 6 months
Secondary Endurance time during a sub-maximal exercise (80% of maximum load) Baseline, at 3 months and at 6 months
Secondary Baseline Dyspnea Index (BDI) The BDI is an interviewer-administered rating of severity of dyspnea at a single state. It provides a multidimensional measurement of dyspnea based on 3 components It comprises 3 domains (functional impairement, magnitude of task and magnitude of effort) scoring from 0 (very severe) to 4 (no impairment) with a recall of the last two weeks. The total score ranges from 0 to 12, the lower the score, the worse the severity of dyspnea. Baseline, at 3 months and at 6 months
Secondary Transition Dyspnea Index (TDI) scores The TDI measures changes in each domain of dyspnea severity from the baseline as established by the BDI. The change is rated by seven grades ranging from -3 (major deterioration) to +3 (major improvement). The total score ranges from - 9 to + 9 Baseline, at 3 months and at 6 months
Secondary The modified Medical Research Council (mMRC) scale The mMRC scale is a self-assessed unidimensional scale rating the impact of dyspnea on physical activity in everyday life. The patient chooses the answer that best describes his level of limitation related to dyspnea among 5 proposals. The score is between 0 (absence of dyspnea) to 4 (permanent dyspnea). The MCID considered is 1 unit although data are limited. Baseline, at 3 months and at 6 months
Secondary Multidimensional Dyspnea Profile (MDP) scores The MDP questionnaire is an 11-item hetero-questionnaire evaluating both sensory and affective dimensions of dyspnea, respectively the sensation produced by the respiratory stimulus and the emotion associated with this sensation. Baseline, at 3 months and at 6 months
Secondary ACQ-5 score The ACQ-5 is a shortened version of the ACQ that assesses asthma symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) omitting the forced expiratory volume in 1 second measurement and short acting beta antagonist use from the original ACQ score. Patients are asked to recall how their asthma has been during the previous week by responding to 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-5 score is the mean of the responses. Mean scores of =0.75 indicate well-controlled asthma, scores between 0.75 and <1.5 indicate partly controlled asthma, and a score =1.5 indicates not well controlled asthma . Individual changes of at least 0.5 are considered to be clinically meaningful. Baseline, at 3 months and at 6 months
Secondary AQLQ score The Asthma Quality of Life Questionnaire (AQLQ) is a 32-item, 4-domain instrument that can either be self- or interviewer-administered. The recall-time is two weeks. The four domains covered are: (i) symptoms (11 items), (ii) activity limitation (12 items, 5 of which are individualized), (iii) emotional function (5 items), and (iv) environmental exposure (4 items). Each item is ranked by the patient using a 7-point Likert scale ranging from 1 (severely impaired) to 7 (not impaired at all). Scores range from 1 to 7, higher scores indicate better quality of life and a minimally important difference (for overall scores and for each sub-domain) has been established at 0.5. Baseline, at 3 months and at 6 months
Secondary Hospital Anxiety and Depression scores (HADS) Depressive symptoms will be assessed using The Hospital Depression and Anxiety Scale.The scale allows to detect anxiety and depression using 14 items rated from 0-3. Baseline, at 3 months and at 6 months
Secondary Respiratory capacity by Spirometry Baseline, at 3 months and at 6 months
Secondary Respiratory capacity by plethysmography Baseline, at 3 months and at 6 months
Secondary Forced inspiratory by Spirometry Baseline, at 3 months and at 6 months
Secondary Ventilatory function by Spirometry Baseline, at 3 months and at 6 months
Secondary Forced oscillation by impulse oscillometry (the Tremoflo ® oscillometry system) Baseline, at 3 months and at 6 months
Secondary Frequency of serious and non-serious side effects Baseline, at 3 months and at 6 months
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device